Yamini Tablet contains Ethinyl Estradiol (0.03 mg) and Drospirenone (3 mg), a combination of synthetic estrogen and progestin used primarily for oral contraception. Ethinyl Estradiol is a potent estrogen that helps regulate the menstrual cycle, while Drospirenone is a progestin with anti-mineralocorticoid properties, which helps prevent ovulation and alters the endometrial lining to reduce the likelihood of implantation. Yamini Tablet is indicated for the prevention of pregnancy in women seeking reliable birth control. It may also be prescribed to manage menstrual disorders such as dysmenorrhea, menorrhagia, or to treat acne vulgaris in women requiring contraception. The medication should be taken orally once daily, preferably at the same time each day, following the prescribed regimen to ensure maximum efficacy. Contraindications include a history of thromboembolic disorders, hormone-sensitive cancers, uncontrolled hypertension, or liver disease. Common side effects may include nausea, breast tenderness, headache, and changes in menstrual bleeding patterns. Patients should be advised to report any signs of thrombosis, severe abdominal pain, or visual disturbances promptly. Yamini Tablet does not protect against sexually transmitted infections. Consultation with a healthcare professional is essential before initiating therapy to assess individual risks and benefits.